Advil NDA approval
This article was originally published in The Tan Sheet
Wyeth Consumer Healthcare receives agency clearance for Advil Cold & Sinus Liquigels May 30. Approved under NDA 21-374, liquigels contain 200 mg ibuprofen, 30 mg pseudoephedrine hydrochloride for "temporary relief" of cold, sinusitis or flu symptoms. Wyeth could be looking to spark new life into its cold and allergy brands, which collectively saw food, drug, mass sales drop 14% to $86 mil. for the 52 weeks ended April 21, according to data from Information Resources, Inc. (Chicago). Advil Cold & Sinus products currently rank ninth in the category, with 52-week sales totaling $40.2 mil. (down 5.2%); the line debuted in 1989. Approval is second this year for Wyeth's Advil franchise; firm will extend its pediatric line with Children's Advil Cold by year end (1"The Tan Sheet" April 29, 2002, p. 5)...
You may also be interested in...
Wyeth Consumer Healthcare's Advil franchise will expand into the pediatric cold category with Children's Advil Cold ibuprofen/pseudoephedrine oral suspension, which is slated to launch later this year
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.